感染性分子克隆衍生的马传染性贫血病毒的免疫学特性

将马传染性贫血病毒驴白细胞毒疫苗(DLA—EIAV)、DLA—EIAV感染性分子克隆衍生毒(vOK8226)以及强弱毒嵌合毒(vOKVltr)分别接种健康马，并于接种后第220d，用EIAV强毒辽宁株(L-EIAV)攻击，观察临床变化，并测定接种后各结构蛋白的抗体变化。结果发现，攻毒后，2匹非免疫对照马和克隆衍生毒接种组中的1匹马体温均出现典型的稽留热并死亡，死亡马呈现典型的马传染性贫血的病理组织学变化，其他免疫马未见任何临床变化；在攻毒后第450d剖杀所有存活马，也未见任何病理组织学变化。抗体检测结果表明，免疫接种后攻毒前各组p11和p9抗体均检测不到，嵌合毒接种组p15、p26和gp45抗体水平高于其他组。攻毒后非免疫对照马体内抗p9、p11、p15、p26和gp45抗体均显著升高，并持续至死亡；嵌合病毒接种马体内各结构蛋白抗体水平与攻毒前没有显著变化，克隆衍生毒接种马体内各结构蛋白抗体水平比攻毒前有所升高。通过临床观察、病理组织学检测以及攻毒后各结构蛋白抗体记忆反应情况分析，置换了强毒LTR的DLA—EIAV感染性分子克隆衍生毒(强弱毒嵌合病毒)免疫马能够抵抗马传染性贫血病毒强毒的攻击，获得完全保护，而DLA—EIAV感染性分子克隆衍生毒免疫马未能完全抵抗强毒的攻击。     

马传染性贫血病毒嵌合毒接种马攻毒后免疫病理学观察

本试验将马传染性贫血病毒(EIAV)嵌合毒、克隆 毒、疫苗毒分别接种健康马,接种后7个月,用马传贫 强毒攻击。攻毒后对发病死亡马和未死亡迫杀马做 病理解剖学和病理组织学观察,以研究不同毒株对试 马的免疫保护情况。     

马传染性贫血病毒弱毒疫苗S2基因在体内变异分析

为研究马传染性贫血病毒(EIAV)驴白细胞弱毒疫苗EIAVDLV121的S2基因在马体内的变异规律,本研究选用4匹成年马,其中2匹(#1、#2)接种EIAVDLV121,另外2匹作为对照.免疫后监测马体温、血小板含量以及病毒载量结果显示,免疫马未出现马传染性贫血体征.通过RT-PCR方法检测病毒S2基因在感染马体内不同时期的基因序列,结果显示,免疫马体内EIAVDLV121 S2蛋白的突变主要发生在氨基酸第17位、22位、39位、41位、51位和55位.另外,#1马免疫后70 d以及#2马免疫后第14 d和第28 d检测疫苗毒S2蛋白序列与EIAVDLV121亲缘关系较近,而#1马免疫后第42 d、第112 d和第140 d的疫苗毒S2蛋白序列与EIAVDLV121的致病性亲本强毒株EIAVDN40亲缘关系最近.本研究结果有助于对EIAV及EIAV疫苗株在马体内感染进程的研究.     

牛传染性鼻气管炎弱毒与牛病毒性腹泻弱毒抗原免疫干扰的研究

本试验使用3~6月龄健康易感牛9头(牛传染性鼻气管炎病毒(IBRV)和牛病毒性腹泻病毒(BVDV)抗原、抗体均阴性),共分3组,每组3头犊牛。第1组首免肌肉注射IBRV-LNM弱毒疫苗株种毒,接种1周后,每头牛接种BVDV-SM弱毒疫苗株;第2组只接种BVDV-SM弱毒疫苗株种毒,接种时间同第1组;第3组为对照组,接种MDBK细胞培养液。接种BVDV-SM疫苗毒后每周采血至疫苗毒接种后28 d,测定接种后BVDV抗体效价,并采用BVDV-JL检验用强毒进行攻毒试验。结果表明,第1组与第2组试验动物血清中牛病毒性腹泻病毒抗体水平无明显差异,能够抵抗BVDV-JL强毒攻击达到免疫保护的效果,说明牛传染性鼻气管炎病毒IBRV-LNM弱毒疫苗株接种后在牛体内对牛病毒性腹泻病毒BVDV-SM疫苗毒不产生免疫干扰作用。     

猪细小病毒病弱毒疫苗免疫效力评价及临床免疫试验

为制定猪细小病毒病弱毒疫苗效力检验的标准,用3批猪细小病毒病弱毒疫苗进行接种猪与接种豚鼠的平行试验;同时进行临床免疫试验。3批疫苗接种豚鼠和猪后定期进行PPVHI抗体检测;猪于免疫后攻毒,并进行病毒分离。免疫母猪在怀孕早期进行强毒攻击,40d扑杀进行病毒分离。用3批疫苗免疫后备母猪统计产仔成绩。结果显示,豚鼠接种后21d、猪接种后7d全部产生抗体反应。免疫攻毒的猪均未从血浆和内脏中分离到病毒,而从对照猪分离到病毒;怀孕母猪强毒攻击后扑杀,胎儿病毒分离均为阴性,而对照猪胎儿病毒分离为阳性;统计数据表明免疫猪的产仔成绩比未免疫猪高,平均每窝多产活仔1.85头,少产死胎木乃伊胎0.65头。结果表明,当免疫豚鼠PPV HI≥64时,免疫猪能抵抗PPV强毒攻击,两者呈正相关;免疫母猪的攻毒试验表明免疫母猪能抵抗PPV经胎盘感染;临床免疫试验证明疫苗具有良好的免疫原性和安全性。     

检测马传贫强毒感染马与弱毒疫苗免疫马外周血病毒抗原的研究

从马传贫强毒急性感染马的外周血白细胞、血浆、血清中可检出马传贫病毒抗原;从亚急性感染马外周血的白细胞、血浆中可检出马传贫病毒抗原;从无症状慢性马外周血的白细胞中偶尔能检出马传贫病毒抗原。对9匹马传贫驴白细胞弱毒疫苗免疫马连续跟踪3个月,从外周血的白细胞、血浆、血清中均未检出马传贫病毒抗原。     

带有组氨酸标签的马传染性贫血病毒感染性分子克隆的构建

马传染性贫血(EIA)弱毒疫苗的广泛使用存在野毒和疫苗毒鉴别困难的问题.本研究以已构建的马传染性贫血驴白细胞弱毒疫苗株的感染性分子克隆(pOK8266)为基础,在其S2基因内引入NspV酶切位点,将人工合成的编码6个组氨酸的寡核苷酸插入NspV位点,获得带有组氨酸标签的重组质粒pOK8266-HIS.将pOK8266-HIS转染驴白细胞,将驴白细胞转染产物传至第6代时,在电镜下观察到了典型的马传染性贫血病毒粒子.提取pOK8266-HIS衍生病毒的前病毒基因组DNA,通过PCR扩增和测序表明,衍生病毒基因组中引入了6个组氨酸标签,从而获得了带有分子标志的马传染性贫血弱毒疫苗株,为野毒株和疫苗病毒的鉴别诊断奠定了基础.本研究还证明了S2基因中的插入突变并不影响马传染性贫血病毒的体外复制.     

3种非猪瘟病毒单独或混合感染对猪瘟弱毒疫苗免疫效力的影响

将 2 0头 9月龄左右猪瘟、伪狂犬、猪繁殖与呼吸障碍综合征抗原、抗体阴性猪分成 6组 ,分别利用猪细小病毒(PPV)、猪伪狂犬病毒 (PRV)和猪繁殖与呼吸障碍综合征病毒 (PRRSV)单独或混合感染。 7d后连同对照猪 4头 ,免疫接种猪瘟兔化弱毒疫苗 (HCL V) ,13d后连同 4头阴性对照猪一起攻击猪瘟石门强毒。整个试验期间分别每天测温 ,观察临床症状 ,每周采集扁桃体和血样做各种病毒抗原及抗体检测。结果表明 ,非猪瘟病毒感染 7d后 ,所有各组猪均从体内检测到了相应感染的病原 ,表明 3种非猪瘟病毒感染成功。在攻击猪瘟石门强毒后 2周 ,感染了非猪瘟病毒后接种 HCL V疫苗的 4个免疫组 12头猪除 1头外 ,11头全为猪瘟病毒 (HCV)抗原检测阳性 ,且多呈强阳性 ;而单一 HCL V疫苗免疫组在猪瘟强毒攻击后检测不到 HCV;所有 HCL V疫苗免疫猪均存活 ,而非免疫对照组 4头猪全部在攻毒 16 d内死亡。     

犬细小病毒核酸疫苗制备及免疫试验

以犬细小病毒基因组DNA为模板,应用PCR方法扩增了全长VP1基因,PCR产物经纯化和NotⅠ/BamHⅠ双酶切后与同样处理的真核表达载体pIRES进行连接,转化到感受态细胞JM109中,筛选了真核重组表达质粒pIRESVP1,并进行了序列测定。对6只9月龄犬分别接种不同剂量的pIRESVP1或空载体质粒及生理盐水,8周接种1次,每次接种前采血,测定血清的血凝抑制抗体效价,第2次免疫后即可检测到较高的血清效价。在第3次接种4周后,对全部实验犬进行攻毒,攻毒后第7天及第14天时采血,测定血清的血凝抑制抗体效价。所有接种pIRESVP1疫苗的犬均能抵抗CPV强毒的攻击,而接种空载体质粒和生理盐水的对照犬则全部发病。证明所构建的核酸疫苗(pIRESVP1)能使犬免受犬细小病毒强毒的感染。     

感染鸡贫血病毒雏鸡ND免疫后血清Igs和HI抗体的动态变化

本试验对１日龄感染鸡传染性贫血病毒（ＣＩＡＶ）雏鸡接种新城疫（ＮＤ）疫苗及其强毒攻击后外周血液免疫球蛋白ＩｇＧ、ＩｇＭ、ＩｇＡ含量和ＨＩ抗体滴度的动态变化进行研究。结果发现，ＣＩＡＶ感染雏鸡ＮＤ疫苗免疫后，其外周血液ＩｇＧ、ＩｇＭ、ＩｇＡ含量和ＨＩ抗体滴度，于接种ＮＤ疫苗后７￣２８ｄ较未感染ＣＩＡＶ的免疫对照雏鸡明显减少，表明ＣＩＡＶ感染雏鸡对ＮＤ疫苗免疫的体液免疫应答功能明显降低。ＮＤ强毒攻击后     

马传染性贫血病毒自然感染马LTR序列分析

我国从20世纪70年代开始使用EIAV弱毒疫苗后,在全国范围内基本控制了马传贫的发生,我们从现地少数EIAV琼扩阳性马外周血中扩增并克隆了二株EIAV前病毒5'LTR序列,并与国内外毒株5'LTR序列进行了比较分析,发现中国EIAV LTR特有的特异性细胞转录因子结合基序,同时发现PEA2位点不是强毒特有的基序,在弱毒中亦发现该基序.     

Differential responses of Equus caballus and Equus asinus to infection with two pathogenic strains of equine infectious anemia virus

Most in vivo studies with equine infectious anemia virus (EIAV) have been performed in horses and ponies (Equus caballus) with little published information available detailing the clinical responses of donkeys (Equus asinus) to infection with this virus. Consequently, donkeys were inoculated with two strains of EIAV (EIAV(PV) and EIAV(WY)) which have been documented to produce disease in E. caballus. Four ponies, 561, 562, 564 and 567 and two donkeys, 3 and 5 were infected with EIAV(PV) and one horse (94-10) and one donkey (4) were infected with EIAV(WY). Although the horse and ponies all experienced clinical signs of disease, which in some cases were severe, the donkeys remained asymptomatic throughout a 365-day observation period, except for mild transient reductions in platelet counts. The results from serological assays, virus isolation from plasma and detection of plasma-associated viral RNA by RT-PCR, indicated that initial replication of EIAV(PV) and EIAV(WY) was lower in donkeys than in horses and ponies. This conclusion was confirmed using competitive RT-PCR, in which viral RNA levels in the plasma of EIAV(PV)-infected ponies was up to 100,000-fold higher than in infected donkeys during the first 20 days post-infection (dpi). Similar results were obtained in the EIAV(WY)-infected animals, in which viral RNA burdens in the donkey at 20 dpi were 1000-fold less than in the horse. However, infection of donkey and horse monocyte-derived macrophage cultures with EIAV(PV) demonstrated that these cells in vitro were equally susceptible to virus-induced cytopathic effects and yielded similar levels of progeny virus. This result suggests that factors other than host cell permissiveness mediate the clinical differences observed between horses and donkeys infected with EIAV(PV) or EIAV(WY).     

Equine infectious anemia in mules: virus isolation and pathogenicity studies

There appears to be a lack of information concerning responses of mules to natural infection or experimental inoculation with equine infectious anemia virus (EIAV). In the present study EIAV was isolated from mules, for the first time, and its pathogenicity in naturally infected and experimentally inoculated animals was investigated. Two naturally infected (A and B) and three EIAV free mules (C, D and E) were used for this purpose. Mule A developed clinical signs, whereas mule B remained asymptomatic until the end of the study. Mules C and D were each inoculated with 10ml of blood from mule A and developed signs of the disease; they were euthanatized or died at day 22 and 25 post-inoculation, respectively. Mule E served as a negative control. The virus was isolated from the plasma samples of mules with clinical signs of the disease (A, C and D), but not from the asymptomatic mule B. Both proviral DNA and viral RNA were amplified from blood and tissues of the infected animals by nested polymerase chain reaction (nPCR). Antibodies were not detected in the two experimentally infected mules until their natural death or euthanasia. Clinicopathological and laboratory findings showed that, in mules, EIAV produced clinical signs similar to those observed in horses and ponies. Nested PCR proved to be a rapid, sensitive and specific diagnostic method for the detection of EIAV, regardless of the disease stage.     

Serosurveillance for equine infectious anaemia in the Ardahan province of Turkey

Equine infectious anaemia is a retroviral infection of horses. All infected horses, including those that are asymptomatic, become carriers and are infectious for life. In this study, blood samples of all equines in the province of Ardahan were collected. The material consisted of 8,947 equines, including 8,769 horses and 178 donkeys, from Ardahan province in northeastern Turkey. Blood was collected from all horses and donkeys and the sera were analysed for the presence of antibodies to equine infectious anaemia virus (EIAV) using an enzyme-linked immunosorbent assay. The results revealed that none of the horses and donkeys were positive for antibodies to EIAV.     

Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: lack of correlation between in vitro activity and in vivo efficacy

Although CTL are important for control of lentiviruses, including equine infectious anemia virus (EIAV), it is not known if CTL can limit lentiviral replication in the absence of CD4 help and neutralizing antibody. Adoptive transfer of EIAV-specific CTL clones into severe combined immunodeficient (SCID) foals could resolve this issue, but it is not known whether exogenous IL-2 administration is sufficient to support the engraftment and proliferation of CTL clones infused into immunodeficient horses. To address this question we adoptively transferred EIAV Rev-specific CTL clones into four EIAV-challenged SCID foals, concurrent with low-dose aldesleukin (180,000U/m2), a modified recombinant human IL-2 (rhuIL-2) product. The dose was calculated based on the specific activity on equine PBMC in vitro, and resulted in plasma concentrations considered sufficient to saturate high affinity IL-2 receptors in humans. Despite specific activity on equine PBMC that was equivalent to recombinant equine IL-2 and another form of rhuIL-2, aldesleukin did not support the engraftment and expansion of infused CTL clones, and control of viral load and clinical disease did not occur. It was concluded that survival of Rev-specific CTL clones infused into EIAV-challenged SCID foals was not enhanced by aldesleukin at the doses used in this study, and that in vitro specific activity did not correlate with in vivo efficacy. Successful adoptive immunotherapy with CTL clones in immunodeficient horses will likely require higher doses of rhuIL-2, co-infusion of CD4+ T lymphocytes, or administration of equine IL-2.     

鸡传染性法氏囊病超强毒Gx与疫苗毒Gt在鸡体内的复制研究

本试验利用鸡传染性法氏囊病超强毒Gx及其致弱疫苗毒Gt为对象,研究超强毒与弱毒株在鸡体主要免疫器官内的复制情况,以探讨两类毒株表现不同生物特性的原因。分别利用鸡胚半数致死量和鸡胚成纤维细胞半数感染量对超强毒Gx和疫苗株Gt进行病毒滴度的测定;再利用荧光定量RT-PCR对两类毒株进行病毒量的校准。以相同量的病毒对2周龄SPF鸡进行攻毒。攻毒试验表明超强毒Gx能造成47.5%的死亡,法氏囊、脾脏、胸腺等免疫器官均严重损伤;而疫苗毒Gt无致死,且未能造成任何病理可见的损伤。病毒的体内复制情况表明超强毒相对于疫苗毒复制更为迅速,病毒载量更高。     

Protective effects of vaccination with bovine leukemia virus (BLV) Tax DNA against BLV infection in sheep

A DNA vaccination trial was performed on sheep to determine whether vaccination with bovine leukemia virus (BLV) transactivator Tax DNA is effective against BLV infection. Immunization was carried out with cationic liposomes containing the Tax-expressing plasmid DNA and subsequently all sheep were challenged with BLV. BLV titers in peripheral blood mononuclear cell (PBMC) determined by syncytium formation assay and BLV provirus load detected by genomic PCR analysis showed higher levels of virus titers in control sheep than those in Tax-vaccinated sheep. Higher levels of IFN-gamma mRNA expression have been demonstrated in vaccinated sheep after the challenge. These results suggested that Th1 type immune response induced by Tax DNA vaccine inhibited BLV propagation in vaccinated sheep at the early phase of infection.     

Cytotoxic T lymphocytes in protection against equine infectious anemia virus

Cytotoxic T lymphocytes (CTL) are associated with virus control in horses infected with equine infectious anemia virus (EIAV). Early in infection, control of the initial viremia coincides with the appearance of CTL and occurs before the appearance of neutralizing antibody. In carrier horses, treatment with immunosuppressive drugs results in viremia before a change in serum neutralizing antibody occurs. Clearance of initial viremia caused by other lentiviruses, including human immunodeficiency virus-1 and simian immunodeficiency virus, is also associated with CTL and not neutralizing antibody. In addition, depletion of CD8+ cells prior to infection of rhesus monkeys with simian immunodeficiency prevents clearance of virus and the same treatment of persistently infected monkeys results in viremia. Cats given adoptive transfers of lymphocytes from vaccinated cats were protected and the protection was MHC-restricted, occurred in the absence of antiviral humoral immunity, and correlated with the transfer of cells with feline immunodeficiency virus-specific CTL and T-helper lymphocyte activities. Therefore, a lentiviral vaccine, including one for EIAV, needs to induce CTL. Based on initial failures to induce CTL to EIAV proteins by any means other than infection, we attempted to define an experimental system for the evaluation of methods for CTL induction. CTL epitopes restricted by the ELA-A1 haplotype were identified and the MHC class I molecule presenting these peptides was identified. This was done by expressing individual MHC class I molecules from cDNA clones in target cells. The target cells were then pulsed with peptides and used with effector CTL stimulated with the same peptides. In a preliminary experiment, immunization of three ELA-A1 haplotype horses with an Env peptide restricted by this haplotype resulted in CTL in peripheral blood mononuclear cells (PBMC) which recognized the Env peptide and virus-infected cells, but the CTL response was transient. Nevertheless there was significant protection against clinical disease following EIAV challenge of these immunized horses when compared with three control horses given the same virus challenge. These data indicated that responses to peptides in immunized horses needed to be enhanced. Optimal CTL responses require help from CD4+ T lymphocytes, and experiments were done to identify EIAV peptides which stimulated CD4+ T lymphocytes in PBMC from infected horses with different MHC class II types. Two broadly cross-reactive Gag peptides were identified which stimulated only an interferon gamma response by CD4+ T lymphocytes, which indicated a T helper 1 response is needed for CTL stimulation. Such peptides should facilitate CTL responses; however, other problems in inducing protection against lentiviruses remain, the most significant of them being EIAV variants that can escape both CTL and neutralizing antibody. A possible solution to CTL escape variants is the induction of high-avidity CTL to multiple EIAV epitopes.     

Real-time quantitative RT-PCR and PCR assays for a novel European field isolate of equine infectious anaemia virus based on sequence determination of the gag gene

In 2006, an outbreak of equine infectious anaemia (EIA) occurred in Ireland. The initial source of the outbreak is believed to have been contaminated plasma imported from Italy. This paper presents the nucleotide sequence of the gag gene of the virus identified in Ireland (EIAV(Ire)), the first for a European strain of EIAV. Comparison of the gag gene with North American and Asian strains of the virus showed that the gag gene is less well conserved than previously believed, and that EIAV strains can have similar phenotypes despite considerable variations in genotype. On the basis of the deduced sequence of the EIAV(Ire) gag gene, highly sensitive, specific and quantitative RT-PCR and PCR assays were developed, and used to quantify the EIAV nucleic acid in postmortem tissues, plasma and secretions of infected horses. This is the first report of the detection and quantification of EIAV in nasal, buccal and genital swabs by RT-PCR.